C12N 2770/16051
Methods of production or purification of viral material
C12N2770/16051 (Methods of production or purification of viral material) appears on 22 US grants and 30 published applications in this corpus.
Search patents in C12N- Granted patents
- 22
- Published applications
- 30
- Assignees
- 23
- Inventors
- 66
- Latest grant
- 23 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 2 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 2 |
| 2014 | 0 | 2 |
| 2015 | 1 | 1 |
| 2016 | 2 | 5 |
| 2017 | 0 | 1 |
| 2018 | 3 | 1 |
| 2019 | 2 | 2 |
| 2020 | 2 | 4 |
| 2021 | 1 | 0 |
| 2022 | 1 | 2 |
| 2023 | 1 | 3 |
| 2024 | 2 | 1 |
| 2025 | 4 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Rabbit haemorrhagic disease virus (RHDV) vaccines23 Dec 2025US 12,503,493 B2
- Sapovirus vaccines29 Jul 2025US 12,371,455 B2Vst LLC
- Purification of virus like particles29 Apr 2025US 12,286,456 B2Takeda Vaccines, Inc.
- Establishment and suspension acclimation of CRFK adherent cell line, and its application29 Apr 2025US 12,286,647 B1Taizhou Bioally Technology Co., Ltd.
- Norovirus fusion proteins and VLPs comprising norovirus fusion proteins21 May 2024US 11,987,601 B2Aramis Biotechnologies Inc.
- Norovirus mrna vaccines10 Sep 2026US 2026/0263582 A1ModernaTX, Inc.
- Establishment and suspension acclimation of crfk adherent cell line, and its application24 Apr 2025US 2025/0129341 A1Taizhou Bioally Technology Co., Ltd.
- A method for production of self-replicating, nucleic acid-loaded, virus-like particles (vlp-na) and the uses thereof19 Dec 2024US 2024/0417698 A1Arizona Board of Regents on behalf of Arizona State University
- Rabbit haemorrhagic disease virus (rhdv) vaccines22 Jun 2023US 2023/0192776 A1VST LLC dba Medgene Labs
- Norovirus fusion proteins and vlps comprising norovirus fusion proteins26 Jan 2023US 2023/0024533 A1Medicago Inc.
Most cited
By later US patents
- Virus like particle purification12US 8,481,693 B2Takeda Vaccines (Montana), Inc. · 2013
- Purification of virus like particles9US 10,167,320 B2Takeda Vaccines, Inc. · 2019
- Virus like particle purification6US 9,359,410 B2Takeda Vaccines, Inc. · 2016
- Stabilized virus like particles having enhanced mucosal immunogenicity4US 9,439,958 B2Arizona Board of Regents, acting for and on behalf of Arizona State University · 2016
- Virus like particle purification3US 10,172,930 B2Takeda Vaccines, Inc. · 2019